• In April 2026, Dexcom voluntarily initiated Class II global recalls of its G7, ONE and ONE+ iOS and watchOS CGM apps after an FDA enforcement report highlighted a software defect that could delay real-time glucose readings and alerts, increasing the risk of users relying on outdated data to manage hypoglycemia or hyperglycemia.
• This recall underscores how even a low-level software issue in widely distributed digital health tools can quickly become a material patient-safety and product-reliability concern for Dexcom.
• We’ll now examine how this app recall, and the associated patient-safety concerns around delayed glucose alerts, may influence Dexcom’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

DexCom Investment Narrative Recap

To own DexCom, you need to believe continuous glucose monitoring remains central to diabetes care and that DexCom can keep converting new type 2 and international users while defending its strong margins. The G7, ONE and ONE+ app recalls highlight software reliability as a near term operational and reputational risk layered on top of pricing and competition concerns, but there is not yet clear evidence that this specific issue is materially altering the main growth catalyst or guidance.

The launch of Dexcom Flex for type 2 adults not on intensive insulin therapy ties directly into the key catalyst of expanding CGM use beyond the traditional type 1 base. This new system, focused on broader access and simple insights, sits alongside the company’s push into AI enabled tools and could support the conversion of newly reimbursed type 2 lives, provided product reliability concerns such as the current app recall are addressed promptly.

Yet beneath this expansion story, investors should be aware that software quality issues in globally distributed apps can...

DexCom's narrative projects $6.7 billion revenue and $1.4 billion earnings by 2029. This requires 11.7% yearly revenue growth and a $469.6 million earnings increase from $930.4 million.

Uncover how DexCom's forecasts yield a $81.64 fair value, a 11% upside to its current price.

Exploring Other Perspectives

More cautious analysts were already assuming slower progress, with revenue only reaching about US$6.4 billion and earnings around US$1.4 billion by 2029, so you should recognize that this recall could reinforce worries about converting newly covered type 2 patients into active CGM users.

Explore 6 other fair value estimates on DexCom - why the stock might be worth as much as 54% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 12 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.